{"nctId":"NCT01069900","briefTitle":"Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection","startDateStruct":{"date":"2010-07-21","type":"ACTUAL"},"conditions":["Intraabdominal Infections"],"count":458,"armGroups":[{"label":"Moxifloxacin (Avelox, BAY12-8039)","type":"EXPERIMENTAL","interventionNames":["Drug: Moxifloxacin (Avelox, BAY12-8039)","Drug: Ertapenem placebo","Drug: Amoxicillin/Clavulanate placebo"]},{"label":"Comparator Ertapenem","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ertapenem","Drug: Amoxicillin/Clavulanate","Drug: Moxifloxacin placebo"]}],"interventions":[{"name":"Moxifloxacin (Avelox, BAY12-8039)","otherNames":[]},{"name":"Ertapenem","otherNames":[]},{"name":"Amoxicillin/Clavulanate","otherNames":[]},{"name":"Moxifloxacin placebo","otherNames":[]},{"name":"Ertapenem placebo","otherNames":[]},{"name":"Amoxicillin/Clavulanate placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Hospitalized males or females 3 months to 17 years of age\n* Able to obtain parental or legal guardian written informed consent and assent from subjects as applicable by local laws and regulations\n* Expected duration of treatment with antibiotics is a minimum of 3 days administered IV, for a total of 5 to 14 days administered IV or IV followed by PO\n* If the subject is a female of child-bearing potential she must have a negative pregnancy test at the screening visit or be capable of practicing an adequate method of contraception, and agree to continue the same method for 1 month following the TOC visit. Lactating subjects are not to be included.\n* Subjects may be enrolled upon a surgically (laparotomy, laparoscopy, or percutaneous drainage) confirmed cIAI revealing at least one of the following:\n\n  * Gross peritoneal inflammation with purulent exudate within the abdominal cavity\n  * Intra-abdominal abscess\n  * Macroscopic intestinal perforation with diffuse peritonitis OR\n* Subjects may be enrolled on the basis of a suspected cIAI, which must be supported with radiological evidence (ultrasound, abdominal plain films, computed tomography \\[CT\\], magnetic resonance imaging \\[MRI\\]) of gastrointestinal perforation or localized collections of potentially infected material and at least one of the following:\n\n  * Symptoms referable to the abdominal cavity (eg, anorexia, nausea, vomiting or pain)\n  * Tenderness (with or without rebound), involuntary guarding, absent or diminished bowel sounds, or abdominal wall rigidity\n  * Fever\n  * Leukocytosis\n* The subject must be scheduled for a surgical procedure (laparotomy or laparoscopy) or percutaneous drainage.\n\nExclusion Criteria:\n\n* Presumed spontaneous bacterial peritonitis\n* All pancreatic processes including pancreatic sepsis, peripancreatic sepsis, or an cIAI secondary to pancreatitis\n* Early acute or suppurative (nonperforated) appendicitis unless there is evidence of an abscess or peritoneal fluid containing pus and micro-organisms suggestive of regional contamination\n* Infections originating from the female genital tract\n* Known severe immunosuppression. Subjects with known mild immunosuppression (eg, Type I or II diabetes mellitus, trauma, or absolute neutrophil count \\[ANC\\] between 1000 and 1500 cells/mm3) may be enrolled.\n* Congenital or documented acquired QT prolongation\n* Receiving concomitant treatment with QT prolonging drugs\n* History of tendon disease/disorder related to quinolone treatment\n* Pathogenic organisms suspected or identified (eg, Pseudomonas) which are resistant to any of the study drugs\n* Abnormal musculoskeletal findings at baseline assessment; or chronic musculoskeletal disease (eg, juvenile rheumatoid arthritis); or chronic illness with high risk for chronic or recurrent arthritis or tendinitis (eg, cystic fibrosis, chronic inflammatory bowel disease)\n* History of myasthenia gravis","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Adverse Events","description":"An adverse event (AE) was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Clinical Cardiac Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Musculoskeletal Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence Rates of Musculoskeletal Adverse Events by Primary System Organ Class (SOC) and Preferred Term","description":"Musculoskeletal adverse events were classified as following SOCs (preferred terms): \"injury, poisoning and procedural complications\" (forearm fracture, joint injury, ligament sprain, muscle strain) \"musculoskeletal and connective tissue disorders\" (arthralgia, joint swelling, musculoskeletal pain, myalgia). Incidence rates were reported as percentage of subjects categorized under preferred terms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Heart Rate Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3","description":"\"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.4","spread":"19.1"},{"groupId":"OG001","value":"90.4","spread":"16.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"9.7"},{"groupId":"OG001","value":"0.3","spread":"6.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":"17.2"},{"groupId":"OG001","value":"82.6","spread":"16.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"8.9"},{"groupId":"OG001","value":"-0.9","spread":"7.1"}]}]}]},{"type":"SECONDARY","title":"PR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3","description":"The PR interval is defined as the period that extends from the onset of atrial depolarization (beginning of the P wave) until the onset of ventricular depolarization. \"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"136.8294","spread":"18.3554"},{"groupId":"OG001","value":"140.5933","spread":"20.5113"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7123","spread":"8.2587"},{"groupId":"OG001","value":"-0.0203","spread":"8.5631"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"139.4915","spread":"17.3258"},{"groupId":"OG001","value":"139.5685","spread":"20.8174"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5813","spread":"9.2143"},{"groupId":"OG001","value":"1.5616","spread":"9.9322"}]}]}]},{"type":"SECONDARY","title":"RR Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3","description":"The RR interval refers to the respective time interval in the Electrocardiogram. \"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"670.7567","spread":"142.6153"},{"groupId":"OG001","value":"689.3067","spread":"145.5957"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.6429","spread":"74.3401"},{"groupId":"OG001","value":"-3.4797","spread":"56.9955"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"740.4778","spread":"149.0964"},{"groupId":"OG001","value":"754.6027","spread":"150.1203"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2862","spread":"77.7582"},{"groupId":"OG001","value":"10.5137","spread":"67.1124"}]}]}]},{"type":"SECONDARY","title":"QRS Interval Changes in Electrocardiogram (ECG) Profiles From Predose to Post-dose on Treatment Day 1 and Treatment Day 3","description":"The QRS interval represents the time it takes for ventricular depolarization to occur. \"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.0333","spread":"7.8279"},{"groupId":"OG001","value":"88.8067","spread":"7.9264"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.119","spread":"4.3799"},{"groupId":"OG001","value":"1.223","spread":"4.2568"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.2423","spread":"8.0196"},{"groupId":"OG001","value":"89.3904","spread":"7.8198"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2768","spread":"4.123"},{"groupId":"OG001","value":"0.2877","spread":"3.1687"}]}]}]},{"type":"SECONDARY","title":"QT Interval Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3","description":"The QT interval is the period that extends from the beginning of ventricular depolarization until the end of ventricular repolarization. \"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"341.1812","spread":"33.9858"},{"groupId":"OG001","value":"344.2333","spread":"33.5494"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5828","spread":"15.213"},{"groupId":"OG001","value":"1.1149","spread":"11.5744"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"358.3082","spread":"34.0504"},{"groupId":"OG001","value":"356.5822","spread":"35.6653"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0906","spread":"16.1875"},{"groupId":"OG001","value":"3.1644","spread":"11.9586"}]}]}]},{"type":"SECONDARY","title":"Corrected QT (QTc) Interval Calculated (Calc) Bazett Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3","description":"QTc interval Calc Bazett represent the interval corrected for heart rate (QTc) milliseconds (msec) which was calculated by Bazett's method. \"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"419.5872","spread":"19.3278"},{"groupId":"OG001","value":"417.34","spread":"18.5718"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.731","spread":"14.2961"},{"groupId":"OG001","value":"2.2905","spread":"14.2544"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"419.2055","spread":"16.6815"},{"groupId":"OG001","value":"412.7945","spread":"17.0075"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2509","spread":"16.8132"},{"groupId":"OG001","value":"1","spread":"12.5346"}]}]}]},{"type":"SECONDARY","title":"Corrected QT (QTc) Interval Calculated (Calc) Fridericia Changes in Electrocardiogram (ECG) Profiles From Pre-dose to Post-dose on Treatment Day 1 and Treatment Day 3","description":"QTc interval Calc Fridericia represent the interval corrected for heart rate (QTc) msec which was calculated by Fridericia's method. \"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"391.1846","spread":"19.1574"},{"groupId":"OG001","value":"390.9467","spread":"18.4339"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0724","spread":"11.3219"},{"groupId":"OG001","value":"1.9122","spread":"11.3058"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"397.3767","spread":"17.2179"},{"groupId":"OG001","value":"392.6918","spread":"18.8144"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.115","spread":"13.5805"},{"groupId":"OG001","value":"1.774","spread":"9.3328"}]}]}]},{"type":"SECONDARY","title":"Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Interval Calc Fridericia Correction on Treatment Day 1 and During Therapy Day 3","description":"A significant QTc prolongation was considered when the QTc value was more than (\\>) upper limit of normal (ULN) range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. \"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"19.1574"},{"groupId":"OG001","value":"1.3","spread":"18.4339"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":"11.3219"},{"groupId":"OG001","value":"2","spread":"11.3058"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"17.2179"},{"groupId":"OG001","value":"0","spread":"18.8144"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"13.5805"},{"groupId":"OG001","value":"0","spread":"9.3328"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Potentially Clinically Significant Electrocardiogram (ECG) QTc Interval Prolongation - by QTc Calc Bazett Correction on Treatment Day 1 and During Therapy Day 3","description":"A significant QTc prolongation was considered when the QTc value was more than ULN range or was prolonged for 30 msec or 60msec in comparison with the pre-treatment value measured on Day 1. \"N\" signifies subjects who were evaluable for the specified parameter for each arm, respectively. Percentage of subjects with potentially clinically significant ECG data was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.5","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at Test-of-Cure (TOC) Visit","description":"Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Bacteriological Response at Test-of-Cure (TOC) Visit","description":"Bacteriological responses were graded as presumed persistence, presumed eradication or indeterminate.\n\n'Presumed persistence' was applicable for subjects judged to be clinical failures, and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded and invasive procedures are not warranted; Ã­ndeterminate' was applicable when the bacteriological response to the study drug was not valid for any reason (eg, pre-treatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at TOC were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.7","spread":null},{"groupId":"OG001","value":"94.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at Test-of-Cure (TOC) Visit in Subjects With Bacteriologically Confirmed Complicated Intra-abdominal Infection (cIAI)","description":"Clinical responses were graded as clinical cure, failure or indeterminate. 'Clinical cure' defined as a resolution or sufficient improvement of clinical signs and symptoms related to the infection; 'failure' defined as a reappearance of the signs and symptoms of the original infection, or wound infection requiring further systemic antimicrobial therapy; 'indeterminate' defined as those subjects in whom a clinical assessment was not possible to determine (due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent). Percentage of subjects with clinical response at TOC were reported","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":null},{"groupId":"OG001","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at a 'During Therapy' Visit","description":"Clinical responses during therapy visit were graded as clinical improvement, clinical failure, or indeterminate. Clinical improvement defined as a reduction in the severity and/or the number of signs and symptoms of infection; 'clinical failure' defined as a failure to respond or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy.\n\n'Indeterminate' defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent, receipt of an effective concomitant antibacterial for an indication other than the study indication and receipt of less than 3 full days of study drug, etc). Percentage of subjects with clinical response during therapy visit were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.3","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Bacteriological Response at a 'During Therapy' Visit","description":"Bacteriological response during therapy were graded as presumed persistence, presumed eradication, or indeterminate'Presumed persistence' is applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation;'presumed eradication' is defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate is applicable when the bacteriological response to the study drug is not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject is not judged a clinical failure). Percentage of subjects with bacteriological response during therapy visit were reported","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at the End-of-Treatment (EOT) Visit","description":"Clinical responses at EOT were graded as resolution, failure, or indeterminate. 'Resolution' defined as a disappearance of signs and symptoms related to the infection or sufficient improvement of clinical signs and symptoms related to the infection and the subject does not require any further antibiotic therapy or surgical intervention; 'failure' defined as worsening or insufficient lessening of the signs and symptoms of infection requiring a modification or addition of antibacterial therapy; 'indeterminate' is defined as those subjects in whom a clinical assessment is not possible to determine (eg, due to early withdrawal from the study because of adverse events, protocol violation, withdrawn consent; receipt of less than 3 full days of study drug; receipt of an effective concomitant antibacterial for an indication other than study indication; etc). Percentage of subjects with clinical response at EOT were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null},{"groupId":"OG001","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Bacteriological Response at the End of Treatment (EOT) Visit","description":"Bacteriological response at EOT were grades as presumed persistence, presumed eradication or indeterminate. 'presumed persistence' was applicable for subjects judged to be clinical failures and appropriate culture material is not available for evaluation; 'presumed eradication' defined as the absence of appropriate culture material for evaluation because the subject has clinically responded (with a response as a resolution or cure) and invasive procedures are not warranted; 'indeterminate' is applicable when the bacteriological response to the study drug was not valid for any reason (eg, pretreatment culture was negative or culture was not obtained when material was available and the subject was not judged a clinical failure). Percentage of subjects with bacteriological response at EOT were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":301},"commonTop":["Incision site pain","Vomiting","Electrocardiogram QT prolonged","Procedural pain","Wound infection"]}}}